Ketohexokinase Inhibition in NAFLD

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Fructose is a big contributor to the development of non-alcoholic fatty liver disease (NAFLD). Inhibiting ketohexokinase (KHK), the enzyme catalyzing the first committed step in fructose metabolism, is thought to reduced intrahepatic lipid (IHL) content. Pharmacological inhibition of KHK resulted in a decrease in IHL content in NAFLD patients, but additional health effects are still unknown. In this study the investigators aim to look at additional health effects following KHK inhibition (KHKi).
Epistemonikos ID: 01caef609b44a024e6cd235381f299d46e2100a8
First added on: May 13, 2024